Keyword: Keytruda

If Merck gets its way, it won’t be long before the prostate cancer treatment landscape looks pretty different.

BMS investors have been dreading positive kidney cancer results from Merck for months. And those results might even be better than they expected.

Merck’s Keytruda is duking it out with BMS' Opdivo in head and neck cancer, but Keytruda just took one step toward a big edge.

Merck's 2019 sales expectations are on the low side of what analysts expected, intensifying concerns about growth beyond I-O star Keytruda.

The adjuvant use of I-O therapies could be a $29 billion market, currently led by BMS and Roche, according to Credit Suisse analysts.

For the fourth quarter, analysts expect Keytruda to maintain its lead over Opdivo. But it’s Opdivo that could surprise Wall Street, one analyst says.

Merck's latest additions to the multichannel "It's Tru" campaign for cancer drug Keytruda include two TV ads featuring a real oncologist.

Exelixis nabbed an FDA nod for Cabometyx in second-line liver cancer, where Stivarga, Opdivo and Keytruda are already battling it out.

In November, Merck said Keytruda had topped chemo at lengthening the lives of esophageal cancer patients. Monday, it showed the win was a big one.

Key oncology wins helped drive Pfizer and Merck to the top of the Dow in 2018, but the pharma sector faces plenty of hurdles this year.